Newsletter Subject

⚡Ethereum ETF debuts tomorrow

From

riskhedge.com

Email Address

subscribers@riskhedge.com

Sent On

Mon, Jul 22, 2024 03:08 PM

Email Preheader Text

Will you be buying? Ethereum ETF debuts tomorrow The “Trump trade” is on. Banks, oil produ

Will you be buying? [The Jolt with Stephen McBride] Ethereum ETF debuts tomorrow The “Trump trade” is on. Banks, oil producers, and manufacturing stocks are rocketing higher. Markets increasingly seem to think Trump has the election in the bag. Keep two things in mind: #1: Prices often rise more on speculation and anticipation of an event than after the event occurs. Remember how everyone thought solar and wind stocks would go parabolic if Biden won in 2020? The largest clean energy ETF—the iShares Global Clean Energy ETF (ICLN)—nearly quadrupled heading into the election. But it’s been cut in half since Biden’s inauguration. Don’t be surprised if “Trump stocks” surge into November and top out soon after. #2: Buy companies that’ll win regardless of who’s president. If Trump wins, big tech companies will spend tens of billions of dollars on artificial intelligence (AI) infrastructure. If Biden wins, big tech companies will spend tens of billions of dollars on AI infrastructure. Buy great businesses profiting from disruptive megatrends, and the rest will take care of itself. That’s how we’re investing in Disruption Investor. [(Upgrade here.)]( - CRISPR is knocking diseases down like skittles. Last week, gene editing [cured a hemophiliac](. This week, it’s healing sufferers of angioedema, a debilitating rare disorder that triggers crippling bouts of swelling. Some even die when their throats swell shut. Horrific. And there was little we could do to help these folks… until now. Intellia Therapeutics (NTLA) just announced its gene-editing treatment slashed angioedema attacks by an average of 98% in trials! Often referred to as “CRISPR,” gene editing allows scientists to “cut” out bad genes that cause disease and replace them with healthy genes. Doctors essentially infused a regular IV drip with CRISPR technology. This sent tiny, engineered viruses flowing into patients’ livers. These viruses “rip out” the bad genes causing the swelling and replace them with working copies. Two diseases down, 10,000 to go. [Share]( A recent Pew Research survey found a record number of teens find it “hard to have hope for the world.” Someone should tell them we have a magic new technology that’s curing the uncurable. RiskHedge readers know we’re entering a golden age for biotech. It’s the next big transformational disruption, as Matt Ridley (the original Rational Optimist) told me. Continue to invest in world-class biotech businesses. - The first Ethereum ETFs start trading tomorrow morning. Will you be buying? I already own plenty of Ethereum (ETH), and our research suggests crypto is gearing up for another leg higher. Wall Street has steadily bought bitcoin ETFs since they launched in January. Over $1 billion poured into these funds last week alone. The same will happen for Ethereum. The “[infinite bid](” is coming to crypto. And remember, Ethereum is only about one-third the size of bitcoin (BTC). That means it takes less money to move its price. I think Ethereum could attract around 20% of the inflows bitcoin got. What will happen when billions of new dollars flow into Ethereum? Much higher prices, I expect. Congratulations to [RiskHedge Venture](members who tripled their money on the Grayscale Ethereum Trust (ETHE) since we bought it last August. This was a bet on the ETH ETF getting approved, and it’s paid off nicely. The biggest mistake investors make with crypto is thinking you must be “all in” or “all out.” Total skeptic? True believer? Doesn’t matter. What matters is crypto has been the best-performing asset in the world over the past few years. All you have to do is own a little bit. Hedge fund legend Dan Tapiero recently told me about the time he convinced a school endowment to put just 1% of its fund into crypto. That small investment more than 5X’d and is now a meaningful amount of money. If you’re interested in joining Venture, membership is now open again. In last week’s issue, I laid out where we are in the crypto cycle and which cryptos are poised to outperform over the coming months. [See if Venture’s a good fit for you here.]( - Today’s dose of optimism… My friend knows the editor at one of the UK’s most popular newspapers. Management at the newspaper disliked how corporate media uses alarmism and despair to attract an audience. This newspaper decided to run an experiment: only report positive news for one week. Result: Readership dropped 70%. Like it or not, we’re addicted to bad news. The corporate media will continue to give people what they want. To understand the real state of the world, you must seek out the truth. Fortunately, there’s plenty of good news too: - In 1800, 40% of kids died before they hit puberty. Today, it’s less than 4%. - Two hundred years ago, Belgium had the world’s highest life expectancy, at 40. Even the poorest countries have higher life expectancies today. - Drownings of kids under the age of five have plunged by more than two-thirds since 1990. Pessimists sound smart; optimists make money. That’s all for today. I’ll see you Wednesday. Stephen McBride Chief Analyst, RiskHedge Suggested Reading... [Start investing with Stephen](  [We're going small once again...]( Share Your Thoughts on this Article [Post a Comment]( Keep up with RiskHedge on the go. Download the App [Get it on Google Play]( [Download on the App Store]( [QR Code] If someone forwarded you this email and you would like to be added to our email list to receive the Jolt every week, [simply sign up here.]( This email was sent to {EMAIL} as part of your subscription to The Jolt. To opt-out, please visit the [unsubscribe page](. [READ IMPORTANT DISCLOSURES HERE.]( YOUR USE OF THESE MATERIALS IS SUBJECT TO THE TERMS OF THESE DISCLOSURES. Copyright © 2024 RiskHedge. All Rights Reserved RiskHedge | 1417 Sadler Road, PMB 415 | Fernandina Beach, FL 32034

Marketing emails from riskhedge.com

View More
Sent On

06/12/2024

Sent On

06/11/2024

Sent On

30/10/2024

Sent On

17/10/2024

Sent On

15/10/2024

Sent On

14/10/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.